Lycia Therapeutics Prices $318 Million IPO

03:43 AM EDT, 10/23/2026 (MT Newswires) -- Lycia Therapeutics (LYCA) has priced its initial public offering of 17.6 million common shares at $18 each, for expected gross proceeds of about $317.5 million, the company said late Thursday. Underwriters have been granted a 30-day option to purchase up to an additional 2.6 million shares, the biotech company said. Shares are expected to debut on the Nasdaq Global Select Market on Friday under the ticker "LYCA." Closing is expected to occur on Oct. 26, subject to closing conditions.